374 related articles for article (PubMed ID: 11861971)
1. A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans.
Timchalk C; Nolan RJ; Mendrala AL; Dittenber DA; Brzak KA; Mattsson JL
Toxicol Sci; 2002 Mar; 66(1):34-53. PubMed ID: 11861971
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent pharmacokinetic and pharmacodynamic response in preweanling rats following oral exposure to the organophosphorus insecticide chlorpyrifos.
Timchalk C; Poet TS; Kousba AA
Toxicology; 2006 Mar; 220(1):13-25. PubMed ID: 16343727
[TBL] [Abstract][Full Text] [Related]
3. An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat.
Timchalk C; Kousba AA; Poet TS
Toxicol Sci; 2007 Aug; 98(2):348-65. PubMed ID: 17504771
[TBL] [Abstract][Full Text] [Related]
4. Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat.
Timchalk C; Poet TS
Neurotoxicology; 2008 May; 29(3):428-43. PubMed ID: 18394709
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic interaction for a binary mixture of chlorpyrifos and diazinon in the rat.
Timchalk C; Poet TS; Hinman MN; Busby AL; Kousba AA
Toxicol Appl Pharmacol; 2005 May; 205(1):31-42. PubMed ID: 15885262
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of chlorpyrifos and 3,5,6-trichloro-2-pyridinol in rat saliva after chlorpyrifos administration.
Smith JN; Wang J; Lin Y; Klohe EM; Timchalk C
Toxicol Sci; 2012 Dec; 130(2):245-56. PubMed ID: 22874420
[TBL] [Abstract][Full Text] [Related]
7. Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.
Smith JN; Campbell JA; Busby-Hjerpe AL; Lee S; Poet TS; Barr DB; Timchalk C
Toxicology; 2009 Jun; 261(1-2):47-58. PubMed ID: 19397948
[TBL] [Abstract][Full Text] [Related]
8. Effect of in vivo nicotine exposure on chlorpyrifos pharmacokinetics and pharmacodynamics in rats.
Lee S; Poet TS; Smith JN; Busby-Hjerpe AL; Timchalk C
Chem Biol Interact; 2010 Mar; 184(3):449-57. PubMed ID: 20097188
[TBL] [Abstract][Full Text] [Related]
9. Impact of repeated nicotine and alcohol coexposure on in vitro and in vivo chlorpyrifos dosimetry and cholinesterase inhibition.
Lee S; Poet TS; Smith JN; Hjerpe AL; Gunawan R; Timchalk C
J Toxicol Environ Health A; 2011; 74(20):1334-50. PubMed ID: 21899407
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the in vitro kinetic interaction of chlorpyrifos-oxon with rat salivary cholinesterase: a potential biomonitoring matrix.
Kousba AA; Poet TS; Timchalk C
Toxicology; 2003 Jun; 188(2-3):219-32. PubMed ID: 12767693
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy.
Garabrant DH; Aylward LL; Berent S; Chen Q; Timchalk C; Burns CJ; Hays SM; Albers JW
J Expo Sci Environ Epidemiol; 2009 Nov; 19(7):634-42. PubMed ID: 18716607
[TBL] [Abstract][Full Text] [Related]
12. Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model.
Timchalk C; Kousba A; Poet TS
Toxicol Lett; 2002 Sep; 135(1-2):51-9. PubMed ID: 12243863
[TBL] [Abstract][Full Text] [Related]
13. A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation.
Smith JN; Hinderliter PM; Timchalk C; Bartels MJ; Poet TS
Regul Toxicol Pharmacol; 2014 Aug; 69(3):580-97. PubMed ID: 24200834
[TBL] [Abstract][Full Text] [Related]
14. Use of a probabilistic PBPK/PD model to calculate Data Derived Extrapolation Factors for chlorpyrifos.
Poet TS; Timchalk C; Bartels MJ; Smith JN; McDougal R; Juberg DR; Price PS
Regul Toxicol Pharmacol; 2017 Jun; 86():59-73. PubMed ID: 28238854
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibition and toxicokinetics in immature and adult rats after acute or repeated exposures to chlorpyrifos or chlorpyrifos-oxon.
Marty MS; Andrus AK; Bell MP; Passage JK; Perala AW; Brzak KA; Bartels MJ; Beck MJ; Juberg DR
Regul Toxicol Pharmacol; 2012 Jul; 63(2):209-24. PubMed ID: 22504667
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of chlorpyrifos in adult male Long-Evans rats following repeated subcutaneous exposure to chlorpyrifos.
Ellison CA; Smith JN; Lein PJ; Olson JR
Toxicology; 2011 Sep; 287(1-3):137-44. PubMed ID: 21708215
[TBL] [Abstract][Full Text] [Related]
17. Lack of differential sensitivity to cholinesterase inhibition in fetuses and neonates compared to dams treated perinatally with chlorpyrifos.
Mattsson JL; Maurissen JP; Nolan RJ; Brzak KA
Toxicol Sci; 2000 Feb; 53(2):438-46. PubMed ID: 10696792
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific effects of chlorpyrifos on carboxylesterase and cholinesterase activity in adult rats: an in vitro and in vivo comparison.
Chanda SM; Mortensen SR; Moser VC; Padilla S
Fundam Appl Toxicol; 1997 Aug; 38(2):148-57. PubMed ID: 9299188
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the chlorpyrifos metabolite 3,5,6-trichloro-2-pyridinol (TCPy) in rat saliva.
Smith JN; Wang J; Lin Y; Timchalk C
Toxicol Sci; 2010 Feb; 113(2):315-25. PubMed ID: 19920072
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.
Foxenberg RJ; Ellison CA; Knaak JB; Ma C; Olson JR
Toxicology; 2011 Jul; 285(1-2):57-66. PubMed ID: 21514354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
